Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | ABL1 | P00519 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA1 | P00915 | 6/20 | 0.56 |
| ▸ | CA2 | P00918 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | HLCS | P50747 | 5/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839651 | 0.87 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21606796 | 0.85 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21524656 | 0.84 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL19901346 | 0.84 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12724896 | 0.84 | TDP1 (0.68) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL10615187 | 0.83 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21841832 | 0.83 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21841843 | 0.83 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL21841844 | 0.83 | TDP1 (0.65) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL20143684 | 0.82 | TDP1 (0.61) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120195951-A1 | Therapeutic Inhibitor of Vascular Smooth Muscle Cells | KUNZ LAWRENCE L (US) | 2012-08-02 | — | — | US | disclosed |
| US-8158670-B2 | Therapeutic inhibitor of vascular smooth muscle cells | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8097642-B2 | Therapeutic inhibitor of vascular smooth muscle cells | BOSTON SCIENTIFIC SCIMED, INC. | 2012-01-17 | — | — | US | disclosed |
| US-8067022-B2 | Inhibiting stenosis following vascular trauma or disease by administering a conjugate of a vascular smooth muscle binding protein that associates with a cell surface of the vascular smooth muscle coupled to a drug inhibiting cellular activity | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2324829-A1 | Therapeutic inhibitors of vascular smooth muscle cells | Boston Scientific Limited (BB) | 2011-05-25 | — | — | EP | disclosed |
| EP-2298310-A2 | Therapeutic inhibitors of vascular smooth muscle cells | Boston Scientific Limited (BB) | 2011-03-23 | — | — | EP | disclosed |
| EP-2292225-A1 | Dosage form comprising taxol in crystalline form | BOSTON SCIENTIFIC SCIMED LIMITED (BB) | 2011-03-09 | — | — | EP | disclosed |
| EP-0975340-B2 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | BOSTON SCIENT LTD (BB) | 2009-10-28 | — | — | EP | disclosed |
| EP-2098230-A1 | Use of cytoskeletal inhibitors in crystalline form for the inhibition or prevention of restenosis | BOSTON SCIENTIFIC SCIMED LIMITED (BB) | 2009-09-09 | — | — | EP | disclosed |
| US-20090196931-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | KUNZ LAWRENCE L | 2009-08-06 | — | — | US | disclosed |
| WO-1998043618-A2 | USE OF CYTOSKELETAL INHIBITORS FOR THE PREVENTION OF RESTENOSIS | NEORX CORPORATION (US) | 1998-10-08 | — | — | WO | disclosed |
| US-5811447-A | Therapeutic inhibitor of vascular smooth muscle cells | NEORX CORPORATION (US) | 1998-09-22 | — | — | US | disclosed |
| US-5733925-A | ADMINISTERING TAXOL TREATING CARDIOVASCULAR DISORDER | NEORX CORPORATION (US) | 1998-03-31 | — | — | US | disclosed |
| EP-0809515-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1997-12-03 | — | — | EP | disclosed |
| EP-0752885-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1997-01-15 | — | — | EP | disclosed |
| WO-1996025176-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1996-08-22 | — | — | WO | disclosed |
| EP-0752885-A4 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORP (US) | 1996-02-06 | — | — | EP | disclosed |
| EP-0681475-A1 | THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994016706-A1 | THERAPEUTIC INHIBITORS OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994007529-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | NEORX CORPORATION (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090196931-A1 | THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS | MYLK, TNNI3, MYLK2 | TDP1 2152/4885MEN1 3644/4885ABL1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.